

## **BRAND ACCESS**

## Marketplace Dynamics: HIV

Marketplace Dynamics: HIV assesses current and future access landscapes for HIV treatments to support effective identification of opportunities and risks for brands.

- What level of influence do payers and organized providers have on access in the HIV treatments market?
- How will payer and organized provider management and contracting for branded HIV drugs evolve over the next two years, and how should companies prepare for these changes?
- How are payers responding to key events in the HIV drugs market, such as new approvals and updated clinical data?

## Use Marketplace Dynamics: HIV to:

- Closely monitor market evolution
- Recognize access shifts across the payer and organized provider segments
- Assess/predict current and future payer management of the HIV drugs market to develop effective strategies for inline/pipeline brand(s)
- Identify risks for brands, along with opportunities to improve access

| Overview and Access Influencers March                                      | <ul> <li>Road map for improving HIV brand access in 2020</li> <li>Cross-category analysis of prioritization and management of drugs</li> <li>Analysis of management of the HIV market</li> <li>Advocacy group influence on health plan management of HIV drugs</li> </ul>                                                                |
|----------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Insights on Brand Access at<br>Payers in 2020<br>April                     | <ul> <li>Payer use of reimbursement and utilization management tactics, along with protocols, to influence drug use and restrict access of branded HIV drugs</li> <li>Evolving management strategies for branded HIV drugs on the medical benefit</li> <li>Brand-specific line-of-therapy requirements across HIV indications</li> </ul> |
| Organized Provider Management and Evolving Alternative Payment Models June | <ul> <li>Organized provider use of management tools and tactics to guide drug use and specialist treatment decisions</li> <li>Prevalence of alternative payment models, innovative financial incentives, and performance metrics, and associated impacts on drug access</li> </ul>                                                       |
| Contracting Trends<br>and Insights<br>July                                 | <ul> <li>Impact and prevalence of contracting within the HIV drugs market</li> <li>Key contracting terms and factors driving access gains for branded HIV drugs</li> <li>Evolution of risk-based contracting agreements for branded HIV drugs</li> </ul>                                                                                 |
| Outlook and Insights on<br>Brand Access in 2023<br>September               | <ul> <li>Evolution of access in the branded HIV drugs market</li> <li>Predicted payer and organized provider management tactics for HIV drugs by 2023</li> <li>Brand access predictions for particular scenarios</li> </ul>                                                                                                              |

This product may also include relevant market alerts, real-time assessments of recent changes, or market events. EVERSANA reserves the right to change the timing and/or topics of its syndicated research publications.

Visit: www.EVERSANA.com Phone: 609.397.5282 Email: hsiclientservices@EVERSANA.com